Raptor Pharmaceutical Inc. Receives Notices of Allowance for Key European Patent Applications Protecting Its Cysteamine Portfolio

NOVATO, Calif., April 12, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the European Patent Office has issued a Notice of Allowance for a key patent covering the use of enteric-coated, delayed-release ("DR") oral formulations of cysteamine bitartrate, including Raptor's proprietary microbead formulation, RP103, as well as other formulations of cystamine and cysteamine, as outlined below:

Back to news